Author:
Hui R.,Garon E.B.,Goldman J.W.,Leighl N.B.,Hellmann M.D.,Patnaik A.,Gandhi L.,Eder J.P.,Ahn M.-J.,Horn L.,Felip E.,Carcereny E.,Rangwala R.,Lubiniecki G.M.,Zhang J.,Emancipator K.,Roach C.,Rizvi N.A.
Funder
Merck & Co., Inc., Kenilworth, NJ
Merck & Co., Inc
Reference24 articles.
1. NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer—v4.2016;http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (7 October 2016, date last accessed).
2. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002
3. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion;Blank;Cancer Immunol Immunother,2007
4. Pembrolizumab;Khoja;J Immunother Cancer,2015
5. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N Engl J Med,2015
Cited by
202 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献